Macrophage depletion protects against cisplatin-induced ototoxicity and nephrotoxicity
Science Advances · 26.07.2024 · 10 (30)
DOI: 10.1126/sciadv.adk9878 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 26.07.2024. Verfasst von Cathy Yea Won Sung und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Hearing Biology and Therapeutics, National Institute on Deafness and Other Communication Disorders (NIDCD), NIH, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Cisplatin, Macrophages, Ototoxicity. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCD NIH HHS, Intramural NIH HHS.
Abstract (Originalsprache)
Cisplatin is a widely used anticancer drug with notable side effects including ototoxicity and nephrotoxicity. Macrophages, the major resident immune cells in the cochlea and kidney, are important drivers of both inflammatory and tissue repair responses. To investigate the roles of macrophages in cisplatin-induced toxicities, we used PLX3397, a U.S. Food and Drug Administration–approved inhibitor of the colony-stimulating factor 1 receptor, to eliminate tissue-resident macrophages. Mice treated with cisplatin alone had considerable hearing loss (ototoxicity) and kidney injury (nephrotoxicity). Macrophage ablation resulted in significantly reduced hearing loss and had greater outer hair cell survival. Macrophage ablation also protected against cisplatin-induced nephrotoxicity, as evidenced by markedly reduced tubular injury and fibrosis. Mechanistically, our data suggest that the protective effect of macrophage ablation against cisplatin-induced ototoxicity and nephrotoxicity is mediated by reduced platinum accumulation in both the inner ear and the kidney. Together, our data indicate that ablation of tissue-resident macrophages represents an important strategy for mitigating cisplatin-induced ototoxicity and nephrotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Hearing Biology and Therapeutics, National Institute on Deafness and Other Communication Disorders (NIDCD), NIH, Bethesda, MD, USA.
- Renal Diagnostics and Therapeutics Unit, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.
- Bioinformatics and Biostatistics Collaboration Core, National Institute on Deafness and Other Communication Disorders (NIDCD), NIH, Bethesda, MD, USA.
- Department of Otolaryngology, School of Medicine, Washington University, Saint Louis, MO, USA.
ORCID-Profile: Cathy Yea Won Sung, Peter S T Yuen, John Lee, Katharine Fernandez, Hui Cheng, Robert A Star, Mark E Warchol, Lisa L Cunningham
Förderung
- NIDCD NIH HHS
- Intramural NIH HHS
Zitieren
APA
Sung, C. Y. W., Hayase, N., Yuen, P. S. T., Lee, J., Fernandez, K., Hu, X., Cheng, H., Star, R. A., Warchol, M. E., & Cunningham, L. L. (2024). Macrophage depletion protects against cisplatin-induced ototoxicity and nephrotoxicity. Science Advances, 10(30). https://doi.org/10.1126/sciadv.adk9878
Vancouver
Sung CYW, Hayase N, Yuen PST, Lee J, Fernandez K, Hu X, et al. Macrophage depletion protects against cisplatin-induced ototoxicity and nephrotoxicity. Science Advances. 2024;10(30). doi:10.1126/sciadv.adk9878
BibTeX
@article{Sung2024,
author = {Sung, Cathy Yea Won and Hayase, Naoki and Yuen, Peter S T and Lee, John and Fernandez, Katharine and Hu, Xuzhen and Cheng, Hui and Star, Robert A and Warchol, Mark E and Cunningham, Lisa L},
title = {Macrophage depletion protects against cisplatin-induced ototoxicity and nephrotoxicity},
journal = {Science Advances},
year = {2024},
volume = {10},
number = {30},
doi = {10.1126/sciadv.adk9878}
}
EUVIMED